focus -WSS

focus

author：focus 2025-10-02 23:32:01 - browse：24724

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Novo Nordisk obesity pill bests Wegovy in early trial

knowledge

hotspot

WSS

Excited delirium, Elijah McClain, and emergency physicians

Amylyx ALS drug failure raises questions and concerns

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

The drug industry has found itself all alone in Washington

RSV shot was 90% effective at preventing hospitalizations in kids

Novo Nordisk obesity pill bests Wegovy in early trial

focus

focus

explore

Medicare details structure of new drug price negotiation program

Novo Nordisk obesity pill bests Wegovy in early trial

Cancer drug shortages should be causing more outrage

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Trump demands the U.S. pay no more for drugs than other countries … again

FDA approves Recor Medical high blood pressure device

leisure time

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

FDA approves potent Eli Lilly obesity drug, Zepbound

The drug industry has found itself all alone in Washington

With psoriasis trial ahead, Alumis raises $259 million

Study: New antibiotic targets gonorrhea as well as last existing drug

FDA approves potent Eli Lilly obesity drug, Zepbound

knowledge

knowledge

hotspot

Wikipedia